Orphazyme to get rid of two thirds of employees
The recent FDA rejection of Orphazyme's main candidate is now being felt by its employees.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Biotech firm Orphazyme reports that it has to cut two thirds of its workforce and bid three of its board members farewell.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Amgen gets Japanese authorization for migraine drug
For subscribers
.jpg&w=384&q=75)
